From: Prevalence of oral anticoagulant use among people with and without Alzheimer’s disease
Total = 138 470 | Alzheimer’s disease 68 609 | No Alzheimer’s disease 69 861 | P-Value |
---|---|---|---|
Gender | 0.806 | ||
Women, N (%) | 44 719 (65.2) | 45 491(65.1) | |
Men, N (%) | 23 890 (34.8) | 24 370 (34.9) | |
Age (y), mean ± SD | 80.0 ± 7.1 | 80.0 ± 7.1 | 0.49 |
Occupational social class | < 0.001 | ||
Managerial/professional | 14 329 (20.9) | 15 059 (21.6) | |
Office | 5 793 (8.4) | 5 875 (8.4) | |
Farming/forestry | 13 065 (19.0) | 13 604 (19.5) | |
Sales/industrial/cleaning | 29 203 (42.6) | 27 181 (38.9) | |
Unknown | 6 219 (9.1) | 8 142 (11.7) | |
Anticoagulant use | < 0.001 | ||
None | 52 448 (76.4) | 55 685 (79.7) | |
Oral | 15 816 (23.1) | 13 817 (19.8) | |
Parenteral | 200 (0.3) | 258 (0.4) | |
Both oral and parenteral | 145 (0.2) | 101 (0.1) | |
Oral anticoagulants and Oral antiplatelets | |||
Warfarin | 10 777 (15.7) | 9 471 (13.6) | < 0.001 |
Dipyridamolea | 4 422 (6.4) | 3 486 (5.0) | < 0.001 |
Clopidogrel | 1 055 (1.5) | 1 185 (1.7) | 0.019 |
Prasugrel | -b | 0 | N.Ac |
Direct oral anticoagulants | |||
Dabigatran | 16 (0.02) | 22 (0.03) | 0.359 |
Rivaroxaban | 15 (0.02) | 28 (0.04) | 0.054 |
Comorbidity | |||
Atrial fibrillation | 10 211 (14.9) | 8 550 (12.2) | < 0.001 |
Coronary artery bypass grafting | 2 370 (3.5) | 2 247 (3.2) | 0.014 |
Percutaneous coronary intervention | 1 626 (2.4) | 1 831 (2.6) | 0.003 |
Ischemic stroke | 4 546 (6.6) | 3 921 (5.6) | < 0.001 |
Pulmonary embolism | 925 (1.3) | 948 (1.4) | 0.88 |
Deep venous thrombosis | 1 310 (1.9) | 1 175 (1.7) | 0.001 |
Hemorrhagic stroke | 164 (0.2) | 135 (0.2) | 0.066 |